Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.76 USD
Change Today -0.0078 / -1.02%
Volume 69.4K
SBOTF On Other Exchanges
As of 8:10 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

stellar biotechnologies inc (SBOTF) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/28/14 - $2.36
52 Week Low
07/21/14 - $0.60
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

stellar biotechnologies inc (SBOTF) Related Businessweek News

No Related Businessweek News Found

stellar biotechnologies inc (SBOTF) Details

Stellar Biotechnologies, Inc., a biotechnology company, engages in the aquaculture, research and development, manufacture, and commercialization of keyhole limpet hemocyanin (KLH) protein primarily in Europe, the United States, and Asia. KLH is an immune-stimulating protein used for generation of antibody and cell-mediated immune responses against disease indications, such as cancer, immune disorders, Alzheimer’s, and inflammatory diseases, as well as used for therapeutic vaccine conjugation in immunotherapies. The company also offers in vitro diagnostic kits for preclinical use. It provides its products under the Stellar KLH brand name. The company serves multinational biotechnology and pharmaceutical companies, academic institutions, clinical research organizations, and research centers. Stellar Biotechnologies, Inc. is based in Port Hueneme, California.

stellar biotechnologies inc (SBOTF) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $402.3K
Chief Financial Officer and Corporate Secreta...
Total Annual Compensation: $175.0K
Chief Operating Officer
Total Annual Compensation: $178.3K
Compensation as of Fiscal Year 2014.

stellar biotechnologies inc (SBOTF) Key Developments

Stellar Biotechnologies, Inc. Reports Consolidated Earnings Results for the Second Quarter and Six Months Ended March 31, 2015

Stellar Biotechnologies, Inc. reported consolidated earnings results for the second quarter and six months ended March 31, 2015. For the quarter, the company reported total revenues of $187,627 compared to $114,371 for the same period a year ago. Net loss was $426,164 or $0.01 per basic and diluted share compared to $1,433,854 or $0.02 per basic and diluted share for the same period a year ago. For the year, the company reported total revenues of $400,288 compared to $173,196 for the same period a year ago. Net loss was $1,769,641 or $0.02 per basic and diluted share compared to $7,011,044 or $0.09 per basic and diluted share for the same period a year ago. Net cash used in operating activities was $2,581,458 compared to $2,560,177 for the same period a year ago. The decrease in net loss reported in the quarter and six months ended March 31, 2015 compared to the same periods in 2014 was primarily due to significant noncash gains in the fair value of warrant liability, increased revenues and decreased research and development expenses, net of increased general and administrative expenses and increased noncash foreign exchange loss.

Stellar Biotechnologies Seeks Acquisitions

Stellar Biotechnologies, Inc. (TSXV:KLH) filed a shelf registration in the amount of $100 million and will use the proceeds of the offering to in-license, acquire or invest in complementary businesses, technologies, products or assets

Stellar Biotechnologies Enters into Expanded Supply Agreement with Neovacs

Stellar Biotechnologies, Inc. and Neovacs S.A. have entered into an expanded supply agreement, under which Stellar will supply its Keyhole Limpet Hemocyanin, or KLH, for Neovacs's proprietary Kinoid immunotherapy technology. The new agreement extends and expands the supply contracts previously in place between the Companies, in order to ensure the continued supply of Stellar KLH to Neovacs during its Kinoid clinical trials and to support the expected commercial roll-out of Neovacs' lead product candidate IFNalpha-Kinoid, an immunotherapy being developed for the treatment of systemic lupus erythematosus ("lupus").


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SBOTF:US $0.76 USD -0.0078

SBOTF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SBOTF.
View Industry Companies

Industry Analysis


Industry Average

Valuation SBOTF Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 6.8x
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact STELLAR BIOTECHNOLOGIES INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at